Mark Hamilton

Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy

Zinaida Good, Jay Y. Spiegel, Bita Sahaf et al. · Nature Medicine · 2022 · 224 citations · Full text

Cell Therapy, Cellular Therapies, T-regulatory Cell +10

Systemic Fate of the Adipocyte-Derived Factor Adiponectin

Nils Halberg, Todd Schraw, Zhao V. Wang et al. · Diabetes · 2009 · 194 citations · Full text

Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy

Mark Hamilton, Takeshi Sugio, Troy Noordenbos et al. · New England Journal of Medicine · 2024 · 159 citations · Full text

Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas

Brian J. Sworder, David M. Kurtz, Stefan Alig et al. · Cancer Cell · 2022 · 119 citations · Full text

Lymphoid Neoplasia, Cancer Immunosurveillance, Medicine +7

Discovery and SAR of Novel 2,3‐Dihydroimidazo[1,2‐<i>c</i>]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80‐6946)

William J. Scott, Martin Hentemann, R. Rowley et al. · ChemMedChem · 2016 · 111 citations · Full text